Q-omics provides the consensus-scored KRT17P5 profile across patient tissues and cancer cell-line models. KRT17P5 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, KRT17P5 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, KRT17P5 RNA expression shows 8,163 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight KIRC, and ESCA as cancer lineages where KRT17P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KRT17P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KRT17P5 survival associations across molecular data types. KRT17P5 RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KRT17P5 RNA expression–survival associations across cancer types. High KRT17P5 expression shows unfavorable associations in KIRC, ACC, UVM, COAD, READ and LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for KRT17P5 RNA expression.
This table summarizes KRT17P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KRT17P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KRT17P5 shows lower tumor expression in CHOL and COAD and higher tumor expression in KIRC and PAAD. The KIRC box plot shows higher KRT17P5 RNA expression in tumor versus normal tissue (log2 FC = +0.010, t-test p = .008).
This table shows molecular features associated with KRT17P5 in patient tissues and cancer cell lines. In patient samples, KRT17P5 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
